文献速递儿童血液肿瘤与免疫

儿童慢性髓系白血病停酪氨酸激酶抑制剂后无治疗缓解结局的临床分析

[Clinical analysis of treatment free remission outcomes after discontinuation of tyrosine kinase inhibitors in childhood chronic myeloid leukemia].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2025-01-01

该回顾性队列研究纳入14例经TKI规范治疗后达到稳定DMR≥2年且强烈要求停药的慢性期CML患儿,分析停药后TFR结局。停药后7例失去MMR并全部重启TKI后重获DMR,6个月时8例获得TFR,12和24个月时7例获得TFR,无疾病进展。结论提示部分患儿可安全停药获得TFR,更长的TKI治疗时间和DMR持续时间以及停药前使用二代TKI可能使更多患儿获益。

要点

  • 14例CML患儿停TKI后,6个月时8例获得TFR,12和24个月时7例获得TFR。
  • 7例失去MMR者均立即重启TKI,治疗2.0(2.0,11.0)个月后全部重获DMR,无疾病进展。
  • 停药前更长TKI治疗时间、更长DMR持续时间及使用二代TKI可能让更多患儿获得TFR。

核心结论

  • 部分TKI治疗获得持续稳定DMR≥2年的CML患儿可以停TKI获得TFR。
  • 停TKI前更长的TKI治疗时间和DMR持续时间以及应用二代TKI治疗均可能让更多CML患儿有机会获得TFR。

研究设计与样本

  • 回顾性队列研究,收集河南省肿瘤医院2016年9月30日至2022年1月30日14例年龄<18岁、经TKI规范治疗后达到稳定DMR≥2年且有强烈停TKI意愿的CML慢性期患儿临床资料。
  • 按停TKI后TFR结局分为失去MMR组和未失去MMR组,采用Mann-Whitney U检验和Fisher确切概率法比较两组临床特征。

主要发现

  • 14例停TKI患儿中男7例、女7例,确诊时年龄14.0(4.8,17.0)岁,停TKI时年龄22.0(12.5,27.0)岁,随访时间37.0(27.8,47.5)个月。
  • 7例在停TKI后3.0(2.0,11.0)个月失去MMR;停TKI治疗6个月时8例患儿获得TFR,12和24个月时7例患儿获得TFR。
  • 6例停TKI前应用过二代TKI治疗的患儿中2例分别在停二代TKI后3和11个月失去MMR、4例获得TFR;8例应用伊马替尼治疗的停药患儿中5例在停伊马替尼3.0(2.0,9.0)个月失去MMR、3例获得TFR。
  • 未失去MMR组7例和失去MMR组7例在确诊和停TKI时年龄、TKI治疗至获得DMR的时间、停TKI前TKI治疗时间、停TKI前DMR持续时间、应用二代TKI治疗等方面差异均无统计学意义(均P>0.05)。
  • 7例失去MMR的患儿均立即重启TKI治疗,治疗2.0(2.0,11.0)个月全部重获DMR,无患儿疾病进展;停TKI后仅1例患儿出现轻度骨痛,口服解热镇痛药物可缓解。

关键数值与推荐

  • 停药条件:经TKI规范治疗后达到稳定DMR≥2年且有强烈停TKI意愿的年龄<18岁CML慢性期患儿。
  • TFR结局定义:停药后失去MMR或未失去MMR;失去MMR者立即重启TKI治疗。
  • 随访时间37.0(27.8,47.5)个月;失去MMR时间3.0(2.0,11.0)个月;重获DMR时间2.0(2.0,11.0)个月。

临床怎么用

  • 对于经TKI治疗获得持续稳定DMR≥2年的CML患儿,可在充分评估和强烈意愿下考虑停TKI并密切监测。
  • 停药后失去MMR的患儿应立即重启TKI治疗,本研究中全部重获DMR且无疾病进展。
  • 停药前更长的TKI治疗时间和DMR持续时间以及应用二代TKI可能提高TFR机会,但需个体化评估。

局限性

  • 本研究为单中心回顾性队列研究,样本量仅14例,结论需更大样本验证。
  • 两组临床特征比较均P>0.05,可能受样本量小限制,未能确定TFR的独立预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the treatment-free remission (TFR) outcomes after discontinuation of tyrosine kinase inhibitor (TKI) in children with chronic myeloid leukemia (CML). Methods: In this retrospective cohort study, clinical data of 14 chronic phase CML children aged <18 years who had achieved stable deep molecular response (DMR) for ≥ 2 years after standardized treatment with TKI and had a strong desire to discontinue TKI at Henan Cancer Hospital from September 30, 2016 to January 30, 2022 were collected retrospectively. According to the different TFR outcomes after discontinuation of TKI, patients were divided into loss of major molecular response (MMR) group and without loss of MMR group, differences in clinical characteristics between the two groups of children were analyzed using Mann-Whitney U test and Fisher exact test. Results: Out of 14 children with TKI discontinuation, 7 were male and 7 were female. The age at diagnosis was 14.0 (4.8, 17.0) years, and the age at TKI discontinuation was 22.0 (12.5, 27.0) years. Among them, 8 children were treated with imatinib prior to TKI discontinuation and 6 children were treated with second-line substitution of the second-generation TKI nilotinib or dasatinib prior to TKI discontinuation. The follow-up time was 37.0 (27.8, 47.5) months, and 7 cases lost MMR at the time of discontinuation of 3.0 (2.0, 11.0) months. Eight children gained TFR at 6 months, 7 children gained TFR at 12 and 24 months. Amongst the 6 children who received second-generation TKI prior to TKI discontinuation, 2 children lost MMR at 3 and 11 months and 4 children gained TFR, among the 8 children who discontinued imatinib, 5 children lost MMR at the time 3.0 (2.0, 9.0) months and 3 children gained TFR. The age at diagnosis and TKI discontinuation, the time from TKI treatment to the acquisition of DMR, the duration of TKI treatment before TKI discontinuation, the duration of DMR before TKI discontinuation, and the number of children treated with second-generation TKI were not statistically different between the 7 children in the group that did not lose the MMR and the 7 children in the group that lost the MMR (all P>0.05). All the 7 children with confirmed loss of MMR immediately restarted TKI therapy, and all regained DMR after 2.0 (2.0, 11.0) months of therapy. None of the children had disease progression. After TKI discontinued, only 1 child had mild bone pain, which could be relieved by oral antipyretic analgesic drugs. Conclusions: Children with CML who have achieved a durable stable DMR for≥2 years on TKI therapy can discontinue the TKI and obtain TFR. Both the longer duration of TKI therapy, the longer duration of DMR and the use of second-generation TKI therapy before TKI discontinuation, may allow more children with CML who are expecting TKI discontinuation to have access to TFR. 目的: 分析慢性髓系白血病(CML)患儿停酪氨酸激酶抑制剂(TKI)后的无治疗缓解(TFR)结局。 方法: 回顾性队列研究。收集河南省肿瘤医院2016年9月30日至2022年1月30日经TKI规范治疗后达到稳定深层分子学反应(DMR)≥2年且有强烈停TKI意愿的14例年龄<18岁的CML慢性期患儿的临床资料。按停TKI后TFR结局不同分为失去主要分子学反应(MMR)组和未失去MMR组,采用Mann-Whitney U检验和Fisher确切概率法比较两组患儿临床特征。 结果: 14例停TKI患儿,男7例、女7例;确诊时年龄14.0(4.8,17.0)岁,停TKI时年龄22.0(12.5,27.0)岁。8例患儿停TKI前应用伊马替尼治疗,6例患儿停TKI前二线更换二代TKI尼洛替尼或达沙替尼治疗。14例患儿随访时间37.0(27.8,47.5)个月,7例在停TKI后3.0(2.0,11.0)个月失去MMR。停TKI治疗6个月时,8例患儿获得TFR;12和24个月时,7例患儿获得TFR。6例停TKI前应用过二代TKI治疗的患儿中,2例分别在停二代TKI后3和11个月失去MMR,4例患儿获得TFR;8例应用伊马替尼治疗的停药患儿中,5例在停伊马替尼3.0(2.0,9.0)个月失去MMR,3例获得TFR。未失去MMR组7例患儿和失去MMR组7例患儿的确诊和停TKI时年龄、TKI治疗至获得DMR的时间、停TKI前TKI治疗时间、停TKI前DMR持续时间、应用二代TKI治疗等方面差异均无统计学意义(均P>0.05)。7例失去MMR的患儿均立即重启TKI治疗,治疗2.0(2.0,11.0)个月全部重获DMR。无患儿疾病进展。停TKI后仅1例患儿出现轻度骨痛,口服解热镇痛药物可缓解。 结论: 部分TKI治疗获得持续稳定DMR≥2年的CML患儿可以停TKI获得TFR。停TKI前更长的TKI治疗时间和DMR持续时间以及应用二代TKI治疗均可能让更多CML患儿有机会获得TFR。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao HF, Liang LX, Zu YL, et al. [Clinical analysis of treatment free remission outcomes after discontinuation of tyrosine kinase inhibitors in childhood chronic myeloid leukemia]. Zhonghua Er Ke Za Zhi. 2025. PMID: 39979103. doi:10.3760/cma.j.cn112140-20250115-00039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。